Phosphomevalonate kinase deficiency expands the genetic spectrum of systemic autoinflammatory diseases
Journal of Allergy and Clinical Immunology · 2023-10 · 152 (4) · 1025-1031.e2
DOI: 10.1016/j.jaci.2023.06.013 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Allergy and Clinical Immunology, 2023-10. Verfasst von Jakob Berner und 12 weiteren Autor:innen. Beteiligte Einrichtung: St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria; St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine…. Hauptthemen laut MEDLINE: Phosphotransferases (Alcohol Group Acceptor), Mevalonate Kinase Deficiency, Hereditary Autoinflammatory Diseases, Autoimmune Diseases. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: ERC.
Abstract (Originalsprache)
BACKGROUND: In the isoprenoid biosynthesis pathway, mevalonate is phosphorylated in 2 subsequent enzyme steps by MVK and PMVK to generate mevalonate pyrophosphate that is further metabolized to produce sterol and nonsterol isoprenoids. Biallelic pathogenic variants in MVK result in the autoinflammatory metabolic disorder MVK deficiency. So far, however, no patients with proven PMVK deficiency due to biallelic pathogenic variants in PMVK have been reported. OBJECTIVES: This study reports the first patient with functionally confirmed PMVK deficiency, including the clinical, biochemical, and immunological consequences of a homozygous missense variant in PMVK. METHODS: The investigators performed whole-exome sequencing and functional studies in cells from a patient who, on clinical and immunological evaluation, was suspected of an autoinflammatory disease. RESULTS: The investigators identified a homozygous PMVK p.Val131Ala (NM_006556.4: c.392T>C) missense variant in the index patient. Pathogenicity was supported by genetic algorithms and modeling analysis and confirmed in patient cells that revealed markedly reduced PMVK enzyme activity due to a virtually complete absence of PMVK protein. Clinically, the patient showed various similarities as well as distinct features compared to patients with MVK deficiency and responded well to therapeutic IL-1 inhibition. CONCLUSIONS: This study reported the first patient with proven PMVK deficiency due to a homozygous missense variant in PMVK, leading to an autoinflammatory disease. PMVK deficiency expands the genetic spectrum of systemic autoinflammatory diseases, characterized by recurrent fevers, arthritis, and cytopenia and thus should be included in the differential diagnosis and genetic testing for systemic autoinflammatory diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria; St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria; Ludwig Boltzmann Inst…
- St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria; Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria; CeMM Research Center for Molecular Medicine of the Austrian Academy o…
- St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria; Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria; Medical University of Vienna, Vienna, Austria.
- Amsterdam UMC location University of Amsterdam, Department of Clinical Chemistry, Laboratory Genetic Metabolic Diseases, Amsterdam Gastroenterology Endocrinology Metabolism, Meibergdreef 9, Amsterdam, the Netherlands.
- Department of Pediatrics, Medical University Innsbruck, Innsbruck, Austria; Institute of Developmental Immunology, Medical University Innsbruck, Innsbruck, Austria.
- St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria; Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria.
Förderung
- ERC
Zitieren
APA
Berner, J., van de Wetering, C., Jimenez Heredia, R., Rashkova, C., Ferdinandusse, S., Koster, J., Weiss, J. G., Frohne, A., Giuliani, S., Waterham, H. R., Castanon, I., Brunner, J., & Boztug, K. (2023). Phosphomevalonate kinase deficiency expands the genetic spectrum of systemic autoinflammatory diseases. Journal of Allergy and Clinical Immunology, 152(4), 1025-1031.e2. https://doi.org/10.1016/j.jaci.2023.06.013
Vancouver
Berner J, van de Wetering C, Jimenez Heredia R, Rashkova C, Ferdinandusse S, Koster J, et al. Phosphomevalonate kinase deficiency expands the genetic spectrum of systemic autoinflammatory diseases. Journal of Allergy and Clinical Immunology. 2023;152(4):1025-1031.e2. doi:10.1016/j.jaci.2023.06.013
BibTeX
@article{Berner2023,
author = {Berner, Jakob and van de Wetering, Cheryl and Jimenez Heredia, Raul and Rashkova, Christina and Ferdinandusse, Sacha and Koster, Janet and Weiss, Johannes G and Frohne, Alexandra and Giuliani, Sarah and Waterham, Hans R and Castanon, Irinka and Brunner, Jürgen and Boztug, Kaan},
title = {Phosphomevalonate kinase deficiency expands the genetic spectrum of systemic autoinflammatory diseases},
journal = {Journal of Allergy and Clinical Immunology},
year = {2023},
volume = {152},
number = {4},
pages = {1025--1031.e2},
doi = {10.1016/j.jaci.2023.06.013}
}
EUVIMED